Showing 506 Results
Three leading researchers detail steps to reduce low-value care in the latest edition of The American Journal of Managed Care. Their approach complements a similar effort, the Roadmap for Addressing…
- Low-Value Care
Research conducted by NPC and Discern Health found that shared decision-making and patient decision aid interventions do not always lead to reduced health care costs or utilization.
NPC President and CEO John O'Brien discusses how prescription medicines and the pharmacists who provided them helped people stay healthy at home during the pandemic.
NPC Board Chair Michael Ryan says John M. O’Brien’s arrival as the new president and CEO of NPC reinforces a vital role the biopharmaceutical industry can play in the ongoing debate about health care…
- NPC News
A research survey found that potential government involvement in drug pricing would be unlikely to increase patient affordability.
NPC President and CEO John O'Brien discusses the IQVIA Institute’s new report and takes a closer look at the factors that are driving medication use and health care spending in the United States.
Michael Ciarametaro, Vice President of Research at NPC, reflects on how the scientific revolution of hepatitis C led to a corresponding reimbursement revolution that became a fertile ground for large…
During a recent webinar, NPC President and CEO John M. O'Brien discusses how the Medicare Part D rebate system creates barriers to affordable care for patients.
The COVID-19 pandemic has put a spotlight on the pressing need to address social determinants of health (SDOH). NPC's Dr. Dubois examines the gaps within the existing evidence base and how to improve…
In a column published in Morning Consult, NPC's research team explains why potential government involvement in drug pricing would be unlikely to increase patient affordability.
- Health Spending
What's at risk if we limit innovation? Read the commentary from NPC's John O'Brien in Chain Drug Review.
In a commentary for PharmaBoardroom, NPC's John M. O’Brien explains why we need a focused effort from all health care stakeholders to innovate on how we pay for vital medicines.
NPC Board Chair and BMS SVP Michael Ryan reflects on the biopharmaceutical industry's role in solving global health challenges and how to address misunderstandings about what it takes to bring…
Thanks to an IRS rule, high-deductible health plans with health savings accounts can now cover an expanded list of preventive services and drugs before patients meet their plan’s annual out-of-pocket…
In his AJMC editorial, NPC Interim President and CEO Dr. Robert Dubois says we need to address social determinants of health and improve patients’ lives through approaches based on strong data.
Health care policy experts gathered for a panel discussion, “If the NIH Funds the Research, Should There Be a 'Government Discount?” focused on key questions regarding government funding for research…
- Pandemic Response
An NPC-RTI study provides guidance on quality metrics and practices that can help decision makers understand which budget cap features have the potential to lessen the impact on patient health and…
Stakeholders met virtually for an AMCP Partnership Forum to discuss viable solutions to challenges facing people living with rare disorders, such as affordable and timely access to therapies,…
Finding consensus among health care stakeholders is never easy, and that is certainly true when it comes to the use of care management tools. But there are areas of agreement, especially if we focus…
Given declines in drug prices, the Institute for Clinical and Economic Review’s second report on drug pricing – focusing on a hand-picked, narrow group of medicines rather than the overall landscape …
- Value Assessment